Chlorogenic acid and luteolin synergistically inhibit the proliferation of interleukin-1 β -induced fibroblast-like synoviocytes through regulating the activation of NF- B and JAK/STAT-signaling pathways

Immunopharmacology and Immunotoxicology

Volumn 37, Issue 6, 2015, Pages 499-507

  Lou, Lixia ^a   Liu, Yujun ^b   Zhou, Jingwei ^a   Wei, Yi ^a   Deng, Jiagang ^c   Dong, Bin ^a   Chai, Limin ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b Putuo District Center Hospital   (China)

^c GUANGXI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Chlorogenic acid; fibroblast like synoviocytes; interleukin 1 ; Janus activated kinase signal transducer and activator of transcription 3; luteolin; nuclear factor kappa B

Indexed keywords

CHLOROGENIC ACID; GLYCOPROTEIN GP 130; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; JANUS KINASE 1; LUTEOLIN; PROTEIN P100; STAT3 PROTEIN; JAK1 PROTEIN, RAT; STAT3 PROTEIN, RAT;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVATION; FIBROBLAST LIKE SYNOVIOCYTE; FLOW CYTOMETRY; IMMUNOBLOTTING; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; SYNOVIUM; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; FIBROBLAST; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; CHLOROGENIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FIBROBLASTS; INTERLEUKIN-1BETA; JANUS KINASE 1; LUTEOLIN; NF-KAPPA B; RATS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SYNOVIAL MEMBRANE;

EID: 84947869099     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2015.1095763     Document Type: Article

References (46)

1. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233: 233-255
2. Fan L, Wang Q, Liu R, et al. Citrullinated fibronectin inhibits apoptosis and promotes the secretion of pro-inflammatory cytokines in fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther 2012; 14: R266
3. Huber LC, Distler O, Tarner I, et al. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 669-675
4. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-179
5. Bresnihan B, Cobby M. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: ii22-28
6. Fujisawa K, Aono H, Hasunuma T, et al. Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha. Arthritis Rheum 1996; 39: 197-203
7. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995; 38: 1762-1770
8. Bond M, Baker AH, Newby AC. Nuclear factor B activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 1999; 264: 561-567
9. Georganas C, Liu H, Perlman H, et al. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J Immunol 2000; 165: 7199-7206
10. Morel JC, Park CC, Kumar P, Koch AE. Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFkappaB activation. Lab Invest 2001; 81: 1371-1383
11. Youn J, Kim HY, Park JH, et al. Regulation of TNF-α-mediated hyperplasia through TNF receptors, TRAFs, and NF-B in synoviocytes obtained from patients with rheumatoid arthritis. Immunol Lett 2002; 83: 85-93
12. Choe JY, Park KY, Park SH, et al. Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. Arthritis Res Ther 2013; 15: R26
13. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19: 2548-2556
14. Moncada-Pazos A, Obaya AJ, Viloria CG, et al. The nutraceutical flavonoid luteolin inhibits ADAMTS-4 and ADAMTS-5 aggrecanase activities. J Mol Med 2011; 89: 611-619
15. Shouda T, Yoshida T, Hanada T, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001; 108: 1781-1788
16. Suzuki A, Yamamoto N, Jokura H, et al. Chlorogenic acid attenuates hypertension and improves endothelial function in spontaneously hypertensive rats. J Hypertens 2006; 24: 1065-1073
17. Sonoda M, Nishiyama T, Matsukawa Y, Moriyasu M. Cytotoxic activities of flavonoids from two Scutellaria plants in Chinese medicine. J Ethnopharmacol 2004; 91: 65-68
18. Wu C, Luan H, Zhang X, et al. Chlorogenic acid protects against atherosclerosis in ApoE-/- mice and promotes cholesterol efflux from RAW264.7 macrophages. PLoS One 2014; 9: e95452
19. Sato Y, Itagaki S, Kurokawa T, et al. In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid. Int J Pharm 2011; 403: 136-138
20. Xu JG, Hu QP, Liu Y. Antioxidant and DNA-protective activities of chlorogenic acid isomers. J Agric Food Chem 2012; 60: 11625-11630
21. dos Santos MD, Almeida MC, Lopes NP, de Souza GE. Evaluation of the anti-inflammatory, analgesic and antipyretic activities of the natural polyphenol chlorogenic acid. Biol Pharm Bull 2006; 29: 2236-2240
22. Liu YJ, Zhou CY, Qiu CH, et al. Chlorogenic acid induced apoptosis and inhibition of proliferation in human acute promyelocytic leukemia HL60 cells. Mol Med Rep 2013; 8: 1106-1110
23. Jung HA, Jin SE, Min BS, et al. Anti-inflammatory activity of Korean thistle Cirsium maackii and its major flavonoid, luteolin 5-O-glucoside. Food Chem Toxicol 2012; 50: 2171-2179
24. Sun GB, Sun X, Wang M, et al. Oxidative stress suppression by luteolin-induced heme oxygenase-1 expression. Toxicol Appl Pharmacol 2012; 265: 229-240
25. Manju V, Nalini N. Protective role of luteolin in 1,2-dimethylhydrazine induced experimental colon carcinogenesis. Cell Biochem Funct 2007; 25: 189-194
26. Lee JH, Han Y. Antiarthritic effect of lonicerin on Candida albicans arthritis in mice. Arch Pharm Res 2011; 34: 853-859
27. Hou Y, Wu J, Huang Q, Guo L. Luteolin inhibits proliferation and affects the function of stimulated rat synovial fibroblasts. Cell Biol Int 2009; 33: 135-147
28. Kang BJ, Ryu J, Lee CJ, Hwang SC. Luteolin inhibits the activity, secretion and gene expression of MMP-3 in cultured articular chondrocytes and production of MMP-3 in the rat knee. Biomol Ther 2014; 22: 239-245
29. Mori T, Miyamoto T, Yoshida H, et al. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 2011; 23: 701-712
30. Guo HF, Liu SX, Zhang YJ, et al. High mobility group box 1 induces synoviocyte proliferation in rheumatoid arthritis by activating the signal transducer and activator transcription signal pathway. Clin Exp Med 2011; 11: 65-74
31. 2 nanoparticles on the growth of RSC-364 rat synovial cell. J Nanosci Nanotechnol 2013; 13: 3874-3879
32. Aupperle K, Bennett B, Han Z, et al. NF-kappa B regulation by I kappa B kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 2001; 166: 2705-2711
33. Firestein GS. NF-kappaB: holy grail for rheumatoid arthritis? Arthritis Rheum 2004; 50: 2381-2386
34. Simmonds RE, Foxwell BM. Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 2008; 47: 584-590
35. Miyazawa K, Mori A, Yamamoto K, Okudaira H. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-kappaB and CBF1. Am J Pathol 1998; 152: 793-803
36. Okamoto H, Yamamura M, Morita Y, et al. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997; 40: 1096-1105
37. Ospelt C, Neidhart M, Gay RE, Gay S. Synovial activation in rheumatoid arthritis. Front Biosci 2004; 9: 2323-2334
38. Valencia X, Higgins JM, Kiener HP, et al. Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes. J Exp Med 2004; 200: 1673-1679
39. Konttinen YT, Ainola M, Valleala H, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999; 58: 691-697
40. Pap T, Shigeyama Y, Kuchen S, et al. Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis. Arthritis Rheum 2000; 43: 1226-1232
41. Yamanaka H, Makino K, Takizawa M, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in rheumatoid synovium. Lab Invest 2000; 80: 677-687
42. Alghasham A, Rasheed Z. Therapeutic targets for rheumatoid arthritis: progress and promises. Autoimmunity 2014; 47: 77-94
43. O'Brien CA, Gubrij I, Lin SC, et al. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-B ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 1999; 274: 19301-19308
44. Fonseca JE, Santos MJ, Canhão H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009; 8: 538-542
45. Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011; 22: 83-89
46. Rose-John S, Waetzig GH, Scheller J, et al. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 2007; 11: 613-624